WO2025245826 - USE OF CYCLODEXTRIN AND DERIVATIVE THEREOF AS PROTECTIVE AGENT IN PREPARATION OF TACI-FC FUSION PROTEIN LIQUID PHARMACEUTICAL FORMULATION
National phase entry is expected:
Publication Number
WO/2025/245826
Publication Date
04.12.2025
International Application No.
PCT/CN2024/096556
International Filing Date
31.05.2024
Title **
[English]
USE OF CYCLODEXTRIN AND DERIVATIVE THEREOF AS PROTECTIVE AGENT IN PREPARATION OF TACI-FC FUSION PROTEIN LIQUID PHARMACEUTICAL FORMULATION
[French]
UTILISATION DE CYCLODEXTRINE ET D'UN DÉRIVÉ DE CELLE-CI EN TANT QU'AGENT PROTECTEUR DANS LA PRÉPARATION D'UNE FORMULATION PHARMACEUTIQUE LIQUIDE DE PROTÉINE DE FUSION TACI-FC
[Chinese]
环糊精及其衍生物作为保护剂在制备TACI-Fc融合蛋白液体药物制剂中的用途
Applicants **
REMEGEN CO., LTD.
Inventors
XU, Qiaoyu
BAO, Qianjing
LI, Qi
ZHAO, Yating
MA, Shuonan
FANG, Lei
FU, Xueting
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1761 | |
| EPO | Filing, Examination, Granting | 13648 | |
| Japan | Filing, Examination, Granting | 2306 | |
| South Korea | Filing, Examination, Granting | 2274 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,729
Contact Us
Abstract[English]
Use of a cyclodextrin and a derivative thereof as a protective agent in the preparation of a TACI-Fc fusion protein liquid pharmaceutical formulation. Using the cyclodextrin as the protective agent can enhance the long-term storage stability of a TACI-Fc fusion protein, maintain good biological activity, improve the production efficiency of drugs, and greatly improve administration convenience.[French]
L'invention concerne l'utilisation d'une cyclodextrine et d'un dérivé de celle-ci en tant qu'agent protecteur dans la préparation d'une formulation pharmaceutique liquide de protéine de fusion TACI-Fc. L'utilisation de la cyclodextrine en tant qu'agent protecteur peut améliorer la stabilité au stockage à long terme d'une protéine de fusion TACI-Fc, maintenir une bonne activité biologique, améliorer l'efficacité de production de médicaments, et améliorer considérablement la commodité d'administration.[Chinese]
环糊精及其衍生物作为保护剂在制备TACI-Fc融合蛋白液体药物制剂中的用途。使用环糊精作为保护剂能够提高TACI-Fc融合蛋白长期保存的稳定性，保持良好的生物活性，提升药品生产效率并极大的提高给药便利性。